

Errata to the FDA Briefing Document for January 24, 2023 Antimicrobial Drugs Advisory Committee Meeting

Corrections:

1. On page 31, the last paragraph currently reads:

The Applicant conducted eight phase 1 studies, seven in healthy adults and one in subjects with hepatic impairment. These studies enrolled 150 subjects who received rezafungin ([Table 24](#)). The rezafungin dose in these studies ranged from 50 to 1400 mg and ranged in duration from a single dose to four weekly doses of rezafungin.

This paragraph should read:

The Applicant conducted eight phase 1 studies, seven in healthy adults and one in subjects with hepatic impairment. These studies enrolled 179 subjects who received rezafungin ([Table 24](#)). The rezafungin dose in these studies ranged from 50 to 1400 mg and ranged in duration from a single dose to four weekly doses of rezafungin.